| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $706K | — | — |
| R&D Expense | $24.1M | -6.9% | +17.7% |
| SG&A Expense | $10.7M | +8.0% | +25.4% |
| Operating Income | -$34.1M | +4.8% | -17.5% |
| Net Income | -$31.6M | +4.3% | -29.0% |
| EPS (Basic) | -$0.55 | +3.5% | -31.0% |
| EPS (Diluted) | -$0.55 | +3.5% | -31.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $96.3M | +26.2% | +19.0% |
| Short-term Investments | $131.4M | -28.1% | -50.1% |
| Accounts Receivable | $17.2M | — | — |
| Current Assets | $253.5M | -5.6% | -27.9% |
| Total Assets | $271.9M | -3.6% | -24.8% |
| Current Liabilities | $23.5M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$102.4M | — | — |
| Capital Expenditures | $590K | — | — |
| Investing Cash Flow | $138.8M | — | — |
| Financing Cash Flow | $3K | — | — |
| Free Cash Flow | -$103.0M | — | — |
| +30.3% |
| +49.6% |
| Total Liabilities | $38.6M | +80.3% | +93.2% |
| Stockholders' Equity | $233.3M | -10.5% | -31.7% |